Skip to content
Prescott Bio Canada

Peptide Research Summaries

Short, evidence-oriented summaries of the published pre-clinical and clinical literature for ten peptides we frequently field questions about. Each page covers mechanism, trial outcomes, safety findings, and how the compound compares within its class. Citations are being added as our operator team verifies each PMID or DOI.

Last updated: 2026-08-03

  • Retatrutide

    Triple agonist (GLP-1 / GIP / glucagon). Phase 2 weight-loss trial data.

  • Tirzepatide

    Dual GLP-1 / GIP agonist. SURPASS and SURMOUNT program outcomes.

  • Semaglutide

    GLP-1 receptor agonist. STEP and SUSTAIN trial evidence.

  • BPC-157

    Pentadecapeptide fragment. Pre-clinical tendon, gut, and vascular literature.

  • GHK-Cu

    Copper-binding tripeptide. Skin remodeling and gene modulation studies.

  • MOTS-c

    Mitochondrial-derived peptide. Metabolic homeostasis pre-clinical data.

  • Epitalon

    Tetrapeptide. Telomerase and pineal gland research, mostly Russian literature.

  • NAD+

    Nicotinamide adenine dinucleotide. Sirtuin cofactor and NAD-precursor trials.

  • SS-31 (Elamipretide)

    Cardiolipin-binding mitochondrial peptide. Phase 2 mitochondrial disease trials.

  • Cagrilintide

    Long-acting amylin analog. Co-administered with semaglutide in CagriSema program.

For research use only. These summaries are not medical advice, dosing guidance, or a recommendation to self-administer any compound. Speak with a qualified clinician before making any decision informed by this material.